Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood
Dementia and Neurocognitive Disorders
;
: 1-18, 2020.
Artigo
em Inglês
| WPRIM
| ID: wpr-820815
ABSTRACT
Alzheimer's disease (AD) is pathologically characterized by a long progressive phase of neuronal changes, including accumulation of extracellular amyloid-β (Aβ) and intracellular neurofibrillary tangles, before the onset of observable symptoms. Many efforts have been made to develop a blood-based diagnostic method for AD by incorporating Aβ and tau as plasma biomarkers. As blood tests have the advantages of being highly accessible and low cost, clinical implementation of AD blood tests would provide preventative screening to presymptomatic individuals, facilitating early identification of AD patients and, thus, treatment development in clinical research. However, the low concentration of AD biomarkers in the plasma has posed difficulties for accurate detection, hindering the development of a reliable blood test. In this review, we introduce three AD blood test technologies emerging in South Korea, which have distinctive methods of heightening detection sensitivity of specific plasma biomarkers. We discuss in detail the multimer detection system, the self-standard analysis of Aβ biomarkers quantified by interdigitated microelectrodes, and a biomarker ratio analysis comprising Aβ and tau.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Plasma
/
Biomarcadores
/
Programas de Rastreamento
/
Emaranhados Neurofibrilares
/
Proteínas tau
/
Técnicas e Procedimentos Diagnósticos
/
Diagnóstico
/
Doença de Alzheimer
/
Testes Hematológicos
/
Coreia (Geográfico)
Tipo de estudo:
Estudo diagnóstico
/
Estudo de rastreamento
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Inglês
Revista:
Dementia and Neurocognitive Disorders
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS